Meeting
2016 ASCO Annual Meeting
Effect of cabozantinib treatment on circulating immune cell populations in patients with metastatic triple-negative breast cancer (TNBC).
Authors
Dan G. Duda
Massachusetts General Hospital, Boston, MA
Dan G. Duda , David R. Ziehr , Hao Guo , Mei Ng , William Thomas Barry , Michaela Jane Higgins , Steven J. Isakoff , Jane E. Brock , Elena Ivanova , Cloud Paweletz , Michelle Demeo , Nikhil H. Ramaiya , Beth Overmoyer , Rakesh K. Jain , Eric P. Winer , Sara M. Tolaney
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Triple-Negative/Cytotoxics/Local Therapy
Track
Breast Cancer
Sub Track
Triple-Negative Breast Cancer
Clinical Trial Registration Number
NCT02260531
Citation
J Clin Oncol 34, 2016 (suppl; abstr 1093)
DOI
10.1200/JCO.2016.34.15_suppl.1093
Abstract #
1093
Poster Bd #
198
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
A Phase II study of cabozantinib for metastatic triple-negative breast cancer (TNBC).
First Author: Sara M. Tolaney
Poster
2024 ASCO Annual Meeting
A phase II trial to assess the impact of β2 adrenergic blockade in immune checkpoint inhibitor (ICI)– refractory metastatic triple negative breast cancer (mTNBC).
First Author: Shipra Gandhi
Poster
2021 ASCO Annual Meeting
Assessing safety and activity of cabozantinib combined with lanreotide in gastroenteropancreatic (GEP) and thoracic neuroendocrine tumors (NETs): The phase II LOLA trial.
First Author: Francesca Corti